Eli Lilly has established itself as a powerhouse in the pharmaceutical industry, with a particular focus on diabetes care, oncology, immunology, and neuroscience. The company's recent success has ...

Eli Lilly cut its 2024 revenue guidance, saying demand for its obesity and diabetes drugs had not met its lofty expectations. Eli Lilly expects about $3.5 billion in revenue for its diabetes ...

Companies from Johnson & Johnson to Eli Lilly, Amazon and Nvidia are announcing health-related deals at the JPMorgan Health ...

Eli Lilly has established itself as a powerhouse in the pharmaceutical industry, with a particular focus on diabetes care, oncology, immunology, and neuroscience. The company's recent success has been ...

Pharma major Lupin has acquired Huminsulin brand in India from Eli Lilly ... efforts to expand our diabetes portfolio and provide high quality, affordable health care to our patients," Nilesh ...

This week, Ashley and I are attending the annual JPMorgan Health Care Conference ... costs. Eli Lilly on Tuesday cut its revenue guidance as it said demand for its weight loss and diabetes ...

Novo's Ozempic is approved by the U.S. Food and Drug Administration (FDA) to treat diabetes, while Wegovy is primarily prescribed for obesity care ... has positions in Eli Lilly and Novo Nordisk.

Global pharma major Lupin Limited on Monday announced the acquisition of Huminsulin in India from Eli Lilly ... our diabetes portfolio and provide high-quality, affordable health care to our ...